Recruiting PHASE2 INTERVENTIONAL 1-arm NCT06196697

AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer

A Phase II, Single Arm, Single Center Study of Cadonilimab(AK104) in Combination With Ivonescimab(AK112) Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced Gastric (G) or Gastroesophageal Junction (GEJ) Cancer

Sponsor: Harbin Medical University

Conditions Gastric Adenocarcinoma Gastroesophageal Junction Adenocarcinoma

Interventions Cadonilimab Ivonescimab SOX XELOX

Updated 3 times since 2024 Last updated: Jun 25, 2024 Started: Apr 10, 2024 Primary completion: Jan 31, 2027 Completion: Mar 31, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06196697, this PHASE2 trial focuses on Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma and remains actively recruiting participants. Sponsored by Harbin Medical University, it has been updated 3 times since 2024, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Feb 2024 — Jul 2024 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Harbin Medical University

Data source: Harbin Medical University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Harbin, China